776-02-3

Basic information

• Product Name: 2-HYDROXY-2-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE
• Synonyms: 2-HYDROXY-2-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE;AKOS BBV-003319
• CAS NO: 776-02-3
• Molecular Formula: C₉H₁₀F₃NO
• Molecular Weight: 205.18
• Mol File: 776-02-3.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 301.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.301±0.06 g/cm3(Predicted)
• PKA: 11.59±0.35(Predicted)
• CAS DataBase Reference: 2-HYDROXY-2-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-HYDROXY-2-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE(776-02-3)
• EPA Substance Registry System: 2-HYDROXY-2-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE(776-02-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 776-02-3(Hazardous Substances Data)

Usage

General Description

2-HYDROXY-2-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE is a chemical compound with a molecular formula C10H12F3NO that contains a hydroxyl group and an amine group. It is also known as 4-(Trifluoromethyl)phenethyl alcohol and is used in the production of pharmaceuticals and agrochemicals. It is a colorless liquid with a strong odor and is considered to be a hazardous chemical, with potential health effects including skin and eye irritation, respiratory and gastrointestinal issues, and central nervous system depression. 2-HYDROXY-2-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE is of interest in medicinal chemistry due to its potential pharmacological activities and is used as a building block in the synthesis of various biologically active compounds.

Upstream product

• 168013-75-0 (+/-)-2-hydroxy-2-(4-trifluoromethylphenyl)acetonitrile 
• 73183-23-0 2-(4-(trifluoromethyl)phenyl)-2-((trimethylsilyl)oxy)acetonitrile 
• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 32687-39-1 2-bromo-1-(4-(trifluoromethyl)phenyl)ethanol 
• 339-58-2 2-amino-1-[4-(trifluoromethyl)phenyl]-1-ethanone hydrogen chloride 
• 402-50-6 1-trifluoromethyl-4-vinyl-benzene 
• 383-53-9 2-bromo-1-[4-(trifluoromethyl)phenyl]ethanone 
• 771582-55-9 2-amino-1-[4-(trifluoromethyl)phenyl]ethanone 
• 906482-51-7 2-(4-Trifluoromethyl-phenyl)-2-trimethylsilanyloxy-propionitrile 

Downstream Products

• 720-76-3 5-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine 
• 1383925-61-8 (+/-)-2-(pyrid-2-yl)-5-[4-(trifluoromethyl)phenyl]-1,3-oxazoline 
• 16187-73-8 2-chloro-N-{2-hydroxy-2-[4-(trifluoromethyl)phenyl]ethyl}acetamide 
• 62243-72-5 2-[4-(trifluoromethyl)phenyl]morpholine 
• 7125-73-7 6-[4-(trifluoromethyl)phenyl]morpholin-3-one 
• 864539-94-6 tert-butyl (2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)carbamate 

Relevant articles and documents

RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE

Provided herein are compounds as RORγ antagonist having Formula (I). The compounds or pharmaceutical composition thereof can be used for regulating Retinoid-related orphan receptor gamma t (RORγt). Also provided herein are methods of preparation of the compounds and composition thereof, and uses thereof in treating or preventing RORγt mediated inflammation or autoimmune diseases in mammals, particularly humans.

NOVEL NON-SYSTEMIC TGR5 AGONISTS

The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-sytemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists

A new series of morpholine derivatives has been identified as selective DA D3 receptor antagonists; their in vitro profile and pharmacokinetic data are provided.